key: cord-1014548-mms5dy6i
authors: Kabir, Md Alamgir; Ahmed, Rajib; Chowdhury, Rasheduzzaman; Asher Iqbal, Sheikh Muhammad; Paulmurugan, Ramasamy; Demirci, Utkan; Asghar, Waseem
title: Management of COVID-19: Current Status and Future Prospects
date: 2021-04-17
journal: Microbes Infect
DOI: 10.1016/j.micinf.2021.104832
sha: 88eb405a403d20b1652171bd34da88f12b68f9cc
doc_id: 1014548
cord_uid: mms5dy6i

COVID-19, a highly transmissible pandemic disease, affecting millions of lives around the world. Severely infected patients show acute respiratory distress symptoms. Sustainable management strategies are required to save the lives of the infected people and further preventing spread of the virus. Diagnosis, treatment, and vaccination development initiatives are already exhibited from the scientific community to fight against this virus. In this review, we primarily discuss the management strategies including Prevention of spread, prophylaxis, vaccinations, and treatment for COVID-19. Further, analysis of vaccine development status and performance are also briefly discussed. Global social and economic impact of COVID-19 are also analyzed as part of this review.

A respiratory disease caused by the novel SARS-CoV-2 virus, Coronavirus disease 2019 (COVID- 19) , had outbroken from Wuhan seafood wholesale market in China in late 2019, and spread globally by early 2020 [1] . The clinical manifestations related to the COVID-19 infected patients are usually fever, respiratory distress, cough, shortness of breath, and sometimes asymptomatic [2] . The virus usually transmits via respiratory droplets (saliva, coughing, or sneezing) even via fecal transmission is also possible [2] [3] [4] . It is now a significant public Graphical Abstract health concern globally, and the World Health Organization (WHO) declared this a 'Pandemic' in March 2020 [5] . It has infected more than 129 million people and is responsible for more than 2,820,000 deaths globally by April 03, 2021 and the surge continues [6, 7] .

Within three months of the reported outbreak, scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna, Inc have initiated the first clinical trial of a vaccine, mRNA-1273, against SARS-CoV-2 [8] .

Recently, three vaccines have received Emergency Usage Authorization by the Food and Drug Administration (FDA) in USA. Moreover, several other vaccine candidates have been approved and distributed globally. Besides, at present, several vaccine candidates, including genetic and inactivated whole virus-based vaccines, and treatments including monoclonal antibodies and small molecule antivirals are in the different phases of clinical trials [9, 10] . Despite many of these attempts are ongoing under "warp speed", it may take months to even years to vaccinate entire population around the world. In the meantime, social distancing and lockdown measures have been taken intensely, including closing borders and halting international travels to mitigate viral transmission [11] . All these mitigation measures have severally impacted social encounters and financial dealings. In addition, the development of new mutant strains with various infection rates and their relationship with the uncertainty in responding to the current vaccines are other major problem in the management of this disease.

In this manuscript, we review primarily therapeutic and vaccinations for COVID-19. We discuss therapeutic development strategies, the efficiency of developed drugs, vaccine development technologies with comparative performance analysis, passive immunization, and the worldwide socioeconomic impact by the disease. We concluded this review by discussing the gaps within the diagnostic mechanisms and disease management, and how to overcome those limitations to do proper management and prevention of the disease. [12] ). B) Genomic organization of 30 kb long, positive sense single-stranded RNA (ssRNA) having encoded both structural and nonstructural type proteins (Reprinted from [13] ).

The genomic length is approximately 30 kb and encodes two types of proteins (structural and non-structural proteins) [16] . The full genome of SARS-CoV-2 encodes 13-15 open reading frames (ORFs) and 12 of them are functional. The two encoded polyproteins (ORF1a and ORF1ab) create 16 non-structural proteins (NSP1-NSP16). The encoded structural proteins are spike (S), envelope (E), membrane (M) and nucleocapsid (N) (Fig 1A, 1B) [17] . Besides it also contains two flanking untranslated regions including a 5' cap terminal and 3'-poly-A tail. The ORFs are mainly replicase and protease however the S protein consists of two subunit S1 and S2. Spike protein plays significant contribution in viral entry (S1) and fusion (S2) as a result they are considered a key target for designing/developing drugs/vaccine candidates against COVID-19 [16] .

The first step of management of a disease is to control the spread of infection. Orderly understanding the cause of the COVID-19 pandemic and adopting with different preventive measures plays vital role in controlling a pandemic like COVID-19. Besides, extensive researches on specific treatments, vaccine developments and administration have been ongoing with the advent of SARS-CoV-2. The currently available treatments include small molecule drugs that prevent viral entry into host cells or block viral replication and assembly, as well as biologics/ antibodies that control COVID-19 associated pro-inflammatory immune responses to minimize the disease associated pathologies [18] . On the other hand, vaccines' goal is to develop an adaptive immunity against SARS-CoV-2 by generating the required antibodies to neutralize the virus. Notable milestones in the developments of treatments and vaccines as well as protective actions are summarized below:

The primary route of COVID-19 transmission is via respiratory droplets and COVID-19 can be transmitted even before showing symptoms. To mitigate the virus's spread, two things need to be followed: first, an infected individual needs to be isolated and limited contact with non-infected patients and, secondly, decrease per contact transmission possibility [19] . Human behavior plays an important role in the COVID-19 transmission pattern and adopting with the new behavioral changes are significant to stop the spread of the virus [20] . Accurate and rapid diagnosis is the main key to fight against this kind of pandemic and proved to be fruitful in previous pandemics [21] [22] [23] [24] [25] . Utilization of ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free and Deliverable to end-users) criteria regulated by WHO to develop diagnosis devices should be considered [26] [27] [28] [29] . Isolation of the infected patients and maintaining social distancing actions, including mandating "shelter in place", have been adopted to mitigate the spread of the virus globally, but at a huge cost to society and economy [20] . Proper practice of masks and gloves, hand sanitation, cleaning highly touchable areas with disinfectant have already proved to be beneficial (Fig 2A) [30] . A recent study about the effectiveness of mandating face masks in Germany outlined that the daily use of mask reduced the daily growth of COVID-19 infection by 47% [31] . Some studies also suggest that proper use J o u r n a l P r e -p r o o f of mask reduces the severity of the infection if someone gets infected by COVID-19 [32] . However, the effectiveness of masks also depends on the material or the fabrics it is made of. A study with 14 different types of masks represented that N-95/surgical masks are most effective against droplets ( Fig 2B) [33] . On the other hand, use of face shield also demonstrated to be fruitful from respiratory droplets but only for short time [34] . Gloves has been used since a long time to ensure the safety of healthcare workers in healthcare facilities. CDC has recommended all the healthcare professionals to use gloves who are engaged in providing care to infected people. While disinfecting the exposed/contaminated areas, always, CDC recommended guidelines should be followed [35] . However, maintaining social distancing, creating a barrier where frequent interaction occurs like in a retail stores, avoid public gatherings, avoiding unwanted traveling also plays important role on mitigating the spread of the virus. Different countries, globally, have implemented travel restriction measures to prevent the spread of COVID-19 [36] . A recent study regarding impact of imposing travel restrictions and banning public gatherings also demonstrated significantly reduced reproduction number of the virus infection ( Fig 2C) [37] . However, several safety measures should be considered if travel is necessary specially all the passengers in an aircraft should be tested negative before boarding.

J o u r n a l P r e -p r o o f Figure 2 : A) Prevention of spread by implementing behavioral changes. B) Comparative effectiveness analysis of masks made of different materials to provide protection against droplets (Reprinted from [33] ). C) Estimation of reproduction no reduction after imposing travel restrictions, banning gatherings and closing schools in Brunei (Reprinted from [37] ).

With the outbreak of SARS-CoV-2, scientists/medical practitioners around the globe initially began testing the existing drugs as a repurposing strategy to treat COVID-19 patients without the need of extensive clinical trials. Some of the most widely used/tested drugs include antivirals of other viral diseases, anti-inflammatory agents, immunomodulators, anticoagulants, and vasodilators [38, 39] . While the antiviral drugs are mostly helpful in the early stage of infection, anti-inflammatory/immunomodulatory agents are almost exclusively effective in preventing disease progression in the late stage when there is a need to suppress hyperimmune responses; the anticoagulants can be useful to manage coagulation associated abnormalities caused by COVID-19 [38] .

Most antiviral drugs (protease/polymerase. and reverse transcriptase inhibitors) that underwent clinical trials to treat COVID-19 were originally developed for similar infectious diseases including influenza, SARS-CoV, MERS, HIV, and Ebola with an understanding that known drugs that have worked against an infectious disease will also work against COVID-19 [40] .

Results from previous studies on diverse viruses reveal that, in many cases, while the viral proteases play essential roles in the intracellular processing of structural polyprotein into individual proteins for viral assembly, host cell proteases such as type 2 transmembrane serine protease (TMPRSS2) promote viral uptake by activating envelope glycoproteins [38] . Screening of viral protease inhibitors such as lopinavir-ritonavir combination (a.k.a. Kaletra™), which is an effective treatment for HIV infections, did not show a clear benefit in the clinical trials of hospitalized patients with severe COVID-19 [41, 42] when compared to standard of care alone [43] . This observation likely reflects that SARS-CoV-2 has viral proteases that are substantially different from other viral proteases and may not be efficiently inhibited by pan-protease inhibitors. On the other hand, the inhibitors of host cell proteases (e.g. TMPRSS2) that process the SARS-CoV-2 spike protein and facilitate host cell entry appear to hold clear promises [38] . Notably, Nafamostat, a TMPRSS2 inhibitor, effectively inhibited MERS-CoV S protein-initiated membrane fusion [44] , while Camostat mesylate was found to prevent entry of SARS-CoV-2 into lung cells [45, 46] . Both Camostat and Nafamostat are currently under extensive clinical investigations as potential antiviral treatments for COVID-19 [47] . However, another clinical protease inhibitor candidate developed by Pfizer ( PF-07321332) has showed promising antiviral action against SARS-CoV-2 virus in lab studies [48] . Recently, they have started phase-1 J o u r n a l P r e -p r o o f clinical trial (NCT04756531) for this orally administrated therapeutic including single and multiple ascending doses in healthy adults [49] . Moreover, Pfizer is also studying the potent activity of an intravenously (IV) administered inhibitor (PF-07304814) for the hospitalized patients and currently conducting Phase 1b multi-dose clinical trial (NCT04535167) [48, 50] .

Among the tested RNA-dependent RNA polymerase (RdRp) inhibitors, remdesivir, originally developed by Gilead Sciences (US) for Ebola/Marburg diseases, is probably the most promising agent despite mixed results from the clinical trials. Although remdesivir initially failed to demonstrate statistically significant clinical benefits on hospitalized patients with different levels of severity [51] , more focused trials revealed promising data. The results of a double-blinded, randomized, and placebo-controlled trial of 1063 adults demonstrated that patients who were randomized to receive remdesivir had a shorter recovery time compared to those in the placebo group (11 vs. 15 days) [52, 53] . Consequently, the FDA has approved Emergency Usage Authorization (EUA) to treat COVID-19 patients using remdesivir [53] . Among other RdRp inhibitors, EIDD-2801, an investigational drug, developed by Emory Institute for Drug Development (EIDD)/ Ridgeback Therapeutics (US), underwent phase II/III clinical trials (NCT04405570 and NCT04405739) [54] . Both remdesivir and EIDD-2801 are ribonucleotide analogs that non-selectively block replication of multiple RNA viruses, although they appear to work in different ways, meaning they could be complementary [54] . Unlike remdesivir, which is administered intravenously, EIDD-2801 can be administered orally. However, Another study showed that MK-4482/EIDD-2801 successfully reduced the viral load of SARS-CoV-2 in ferret models [55] . MK-4482/EIDD-2801 can be an auspicious antiviral therapeutic for suppressing the spread of COVID-19 in communities. Other polymerase inhibitors include favipiravir/avigan, which was initially developed for influenza in Japan by Fujifilm Toyama Chemical also tested against SARS-CoV-2. Although Favipiravir initially showed promising results in treating patients from Wuhan and Shenzhen with mild or moderate symptoms [56] , more recent trials using favipiravir alone or in combination with another broad-spectrum antiviral drug, umifenovir/arbidol, suggested no significant improvement in clinical recovery; however, the combination product did expedite relief from fever and cough [57] . Moreover, Favipiravir has teratogenic effects on pregnancy; as a result, drug administration should be controlled [58] .

Like other cytopathic viruses, SARS-CoV-2 infections trigger an innate immune response by recruiting macrophages, monocytes and release cytokines and chemokines, and prime T and B lymphocytes for adaptive immune response [38] . In >80% cases, this process is capable of clearing the infection; however, in some patients, a dysfunctional immune response can lead to an overwhelming release of pro-inflammatory cytokines ((such as interferon gamma, interleukin (IL-1, IL-6), and complement factor 5a)) that mediates widespread lung inflammation, requiring intensive care in hospitals. Indeed, many people with COVID-19 do not die from the tissue damage caused by the virus but from an aggravated immune response leading to "cytokine release syndrome", or "cytokine storm" [38] . In such cases, alternative therapeutic strategies consist of suppressing the inflammatory response by immunomodulatory monoclonal antibodies (mAbs) including the IL-6 inhibitors (tocilizumab and sarilumab), and IL-1 blockers (canakinumab) among others [59] . A clinical study for tocilizumab and sarilumab reported that they can reduce the death rate to critically ill patients by blocking the protein to detect IL-6 [60] . The use of corticosteroids, such as dexamethasone, was found to be beneficial in severe patients who required mechanical ventilation but not those in the early stages of infection [61] . In contrast, the antimalarial drugs, chloroquine/hydroxychloroquine, which also may have the beneficial immunomodulatory effects in vivo [62] in addition to their ability to prevent viral entry and endocytosis of SARS-CoV-2 in vitro [63] , have also been tested in several clinical trials either alone or in combination with azithromycin, but did not show any clear benefit in hospitalized patients [64, 65] .

More recent approaches involve artificial intelligence (AI) to conduct exhaustive computational screening of large libraries of "redirected" or "repurposed" drugs against potential SARS-CoV-2 viral targets, followed by clinical investigations on selected candidates [66] . Such examples include losartan (antihypertensive) and ivermectin (anti-parasitic) [67] that were successful in several individual cases, but require larger clinical trials to demonstrate their potentials for COVID-19 management.

Passive immunization is one of the most effective means of treating viral infections by introducing virus-specific antibodies either from recovered patients or from immunized animals/ cells to newly infected individuals (Fig 3A) , [68, 69] , and was first demonstrated in 1890 for the treatment of tetanus and diphtheria [68] . Passive immunization involves the process of obtaining serum from immune individuals (convalescent plasma), concentrating the immunoglobulin antibodies (hyperimmune immunoglobulins), or developing isolated antibodies (polyclonal or monoclonal) using an immunogen in animal models or cell lines [18, 70] . This treatment is rapid in its action and can generate an immune response within hours or days, which is substantially faster than vaccines. Furthermore, antibody treatment has the potential to override the deficient immune system, especially in severe cases, when an infected individual is not in a condition to receive vaccination [71] . However, passive immunization lasts only for a few days or weeks because this treatment does not involve the generation of memory B cells [71] and can be uncertain for reasons that are context-dependent and not fully understood.

Previous studies on SARS infection have shown that patients who received plasma therapy remained immune for shorter periods and had a reduced mortality rate than the high-dose steroids pulse therapy [72] . Using convalescent plasma (CP) therapy on critically ill patients with COVID-19 reduced viral load measured by RT-PCR. It immediately increased the ratio of the J o u r n a l P r e -p r o o f partial pressure of arterial oxygen (PaO 2 ) to the percentage of inspired oxygen (FiO 2 ) (Fig 3B,  C) [73, 74] . Therefore, considering the growing demand for SARS-CoV-2 treatment in a short Step by step process plasma collection procedure from a recovered COVID-19 patient to infusing to a critically infected patient. B) Case study of a hospitalized patient showing the change in PaO2/FiO2 and CRP before and after the convalescent plasma therapy C) Decrease of viral load shedding reflected in the detection threshold of ORF1b gene using RT-PCR of the same patient's sputum specimen before and after infusing the convalescent plasma (Reprinted from [74] ). time and due to the lack of specific treatments, many countries have adopted CP as their initial line of treatment. However, a clinical trial, including 228 COVID-19 infected patients who received CP and 105 patients who received placebo, didn't show a significant difference in the mortality and other clinical outcomes [75] . Nevertheless, the US-FDA has approved the use of passive immunization in treating COVID-19 for its immediate clinical benefits [76, 77] . However, treatment with CP has several limitations, including difficulty in plasma collection, batch-to-batch variations in neutralizing antibody titers, potential contamination with bloodborne pathogens, and the requirement for matching blood type (Rh factor) [78] .

Administration of isolated/refined antibodies may be a better alternative to CP because they are more antigen-selective and do not have many of the limitations associated with CP's. Several biotechnologies/pharmaceutical companies are currently developing hyperimmune immunoglobulins (H-IGs) as well as polyclonal antibodies (pAbs) from CPs. Notably, the "CoVIg-19 Plasma Alliance" is an alliance formed by a number of companies, including Biotest, BPL, CSL Behring, LFB, Octapharma, and Takeda, that aims to develop plasma-derived H-IGs against COVID-19 [79] . However, the extraction of antibodies is not only technically challenging but also requires expensive laboratory procedures. Besides H-IGs and pAbs, there has been a major push in the US and many other countries to develop monoclonal antibodies (mAbs) to treat COVID-19. Since the identification of SARS-CoV-2, numerous research groups (both academic and industrial) have produced mAbs from the single B cells obtained from SARS-CoV-2 infected patients, or by immunization of humanized animals. Most neutralizing antibodies are aimed to prevent viral entry by masking the S protein from interacting with ACE2 or other host cell receptors, or by preventing the conformational changes of the S protein that enables membrane fusion [80] .

Of particular notes, Elly Lilly developed two antibodies, LY-COV555 (in collaboration with AbCellera) and JS016 (with Shanghai Junshi Biosciences), both of which act by blocking the viral S protein [81] . However, 'bamlanivimab', which is clinically known as LY3819253 (LY-CoV555) was examined to have the better SARS-CoV-2 binding affinity than hundreds of other developed mAbs [82] . It has received the FDA-EUA clearance for treating the COVID-19 patients in the USA [83] . Besides, an antibody cocktail mixture of two human IgG1 antibodies named REGN-COV2 have recently been developed by Regeneron [84] . This cocktail prevents viral entry into human cells by targeting the SARS-CoV-2 Spike protein's receptor-binding domain [85] . The clinical trial (NCT04425629) data suggested a reduced amount of viral load, especially for patients with more significant viral load at the beginning, and this cocktail received FDA-EUA recently [83, 86] . Sorrento Therapeutics is a US-based biotech company that currently tests antibody cocktails in patients with COVID-19. Sorrento's antibody cocktail (COVI-SHIELD) contains three mAbs that can bind to distinct epitopes on SARS-CoV-2 S protein. One of the COVI-SHIELD antibodies, STI-1499, binds specifically to the S1 subunit of the SARS-CoV-2 S protein and can inhibit viral entry as observed in their preclinical studies [87] . Vir Biotechnology, another US company, developed VIR-7831 and VIR-7832 antibodies from recovered SARS patients and S-309 from the memory B cells of SARS-CoV-2 infected patients to target the receptor-binding domain of SARS-CoV-2 S protein [88] . The company is currently conducting Phase 3 trials on COVID-19 patients with S-309 and has partnered with GSK for large scale production [80] . In addition to mAbs, Vir Biotechnology and Alnylam Pharmaceuticals are currently investigating the use of RNA interference to selectively block translation of proteins such as ACE2 and TMPRSS2 that are required for viral entry into host cells. Other companies, including ImmunoPrecise, Ligand Pharmaceuticals, are also in the process of testing their therapeutic antibodies in clinical trials.

Some of the potential limitations of mAbs in the treatment of COVID-19 include unknown bioavailability of passively infused IgG in tissues that are often largely affected by the disease and some inherently associated with undesirable effects of antibody treatments in general, including antibody-dependent enhancement (ADE) of infection [89] . Another important consideration is the effect of genetic diversity in the virus, which is mainly due to the error-prone nature of RdRps in RNA viruses such as CoVs [90] . With currently more than thousands of SARS-CoV-2 genome sequences deposited to date, around 200 recurrent mutations have been identified in the variable regions of the SARS-CoV-2 genome, including the S protein [90], which is the key target for antibody/vaccine design. Therefore, it will be important to monitor the emergence of viral mutations that are either more virulent or that enable stronger adaptation to the human host due to antibody treatments or other factors.

Vaccines are used as preventive medicine that activates the adaptive host immune response to produce neutralizing antibodies against pathogens and induce memory B cells for long term immunity [91] . Because of the high degree of genomic sequence conservation of the CoVs, scientists could begin developing vaccines right after the genomic sequence of SARS-CoV-2 was available, with currently more than hundreds of teams working on different vaccines [92] . Presently, three vaccines have received FDA EUA approval and several others vaccine candidate received approval in different countries around the world and are currently being given to people ( Table 1) . Currently, more than seven dozens of vaccines are in human trials in different phases (Fig 4 (A,B) ) [93] . Vaccine candidates were developed adopting various technologies, including genetic (DNA/RNA-based), recombinant protein-based, vector-based, and inactivated whole viral vaccines (Fig 4C, Fig 5 ) [92, 94, 95] . Many of these trials are supported by the Coalition for Epidemic Preparedness Innovations (CEPI), a charity foundation that was specially formed for developing vaccines to tackle epidemics. The most promising immunogen for developing vaccines for SARS-CoV-2 is the spike (S) protein, but whether the full-length protein or only its receptor-binding domain (RBD) is sufficient to produce effective neutralizing antibodies remains to be investigated [94] .

BioNTech's lipid nanoparticle (LNP)-formulated, nucleoside-modified mRNA vaccine (BNT162b1) demonstrated adequate T-cell responses, and it is the first vaccine to receive FDA clearance in USA [96] [97] [98] . Moderna's LNP-encapsulated mRNA-1273 is an example of another mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of SARS-CoV-2 and is the second vaccine that received FDA EUA approval [96] . Phase 3 data for both of the mRNA-based vaccines demonstrated about 95% efficacy in phase 3 clinical trials [99] , and they are currently being administrated in different countries globally. Currently, these two vaccines are continuing phase 4 clinical trials. Besides, CureVac, a German company, is also working on mRNA-based vaccines that recently underwent Phase 2 and initiated phase 3 trial [100, 101] .

Like mRNA vaccines, the viral vector-based vaccines are also in the advanced stages of clinical investigations. DNA/RNA of the spike protein is conveyed using another vector in this case to create the immune response against SARS-CoV-2. Johnson & Johnson has developed a vaccine named Ad26.COV2.S using human adenovirus to carry the mRNA for the spike protein and completed the phase 3 trials with around 40000 participants [102] . The phase 3 trial showed that the vaccine has 66.3% efficacy for preventing of symptomatic patients and the US-FDA has approved the administration of this vaccine on February 27, 2021 [103] . Besides, Gamaleya Research Institute of Epidemiology and Microbiology in Moscow developed a vaccine "Gam-COVID-Vac" which later named "Sputnik V" combining two Adenoviruses to express S protein inside the host cell and completed its phase 1 and 2 clinical trial (Trial no : NCT04436471) on August 10, 2020 [104] . The Russian authority has approved the vaccine's widespread use before completing the phase 3 clinical trial [105] . However, later, the phase 3 trial reported that it is 92% effective [106] . CanSino biologics (China) has started phase 3 clinical trials for its Ad5-nCoV vaccine with 20,000 participants (Trial no: NCT04526990), World Health Organization (http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/). which utilizes adenovirus type-5 (Ad5) as a vaccine vector [107, 108] . CanSino's Ad5-nCoV vaccine has been approved by the Chinese Military as a "specially needed drug" on June 25, 2020 and is currently one of the approved vaccines for COVID-19. The University of Oxford's Jenner Institute and the British-Swedish pharmaceutical company, AstraZeneca have already completed phase 3 trials on their ChAdOx1/AZD1222 vaccine and it has shown around 76% effective at preventing COVID-19 [109] [110] [111] [112] . The ChAdOx1/ AZD1222 vaccine has received approval from UK's medicines regulator to be distributed in UK beginning of 2021 and currently being administrated in more than 100 countries globally [113] . Both Ad5-nCoV and ChAdOx1/AZD1222 use replication-deficient adenoviruses capable of encoding the spike (S) protein of SARS-CoV-2, thus enabling formation of endogenous antibodies against SARS-CoV-2 [109, 111] . However, recently more than 20 countries have halted the administration of this vaccine due to discrete reporting of rare blood-clotting problems in women (<55 years) [114] . WHO and the European Medicines Agency (EMA) stated that this vaccine is safe and recommends it, though EMA couldn't rule out the possibilities. Another interesting example of an adenovirus-based vaccine formulation includes an oral pill, rather than injectables, made by Vaxart. This USA based company is currently conducting the phase 1 clinical trial (NCT04563702). In addition, Sinovac Biotech and Wuhan Institute of Biological Products, and China National Pharmaceutical Group (Sinopharm) have started the clinical trials of their live attenuated whole virus vaccines on humans [107, 115] . Inactivated vaccines utilize a whole, attenuated strain of the SARS-CoV-2 to initiate the immune response of the human body [116] . Even though the introduced viruses are attenuated, they are still capable of inducing both innate and adaptive immune responses in humans [117] . Inovio has developed a DNA plasmid vaccine, INO-4800, that showed excellent safety and tolerability with 100% immunogenicity [118] . No serious adverse effects in phase 1 were observed, and is currently continuing the phase 2/3 trials [119] . The Japanese biotechnology company AnGes in partnership with Osaka University and Takara Bio, is also working on a DNA vaccine that is in the phase 2/3 stage.

J o u r n a l P r e -p r o o f [120, 121] . Similarly, NVX-CoV2373, by a USA based company Novavax, has also developed a prefusion stabilized recombinant S protein-based vaccine that utilizes a proprietary nanoparticle technology for enhanced immune responses [122, 123] . Other vaccines using the recombinant protein-based platform are made by ExpresS2ion, iBio, Baylor College of Medicine, University of Queensland, and Sichuan Clover Biopharmaceuticals [96] .

All these vaccine platforms have their own advantages and disadvantages. For example, the genetic vaccines are relatively easy to handle, yet they can invoke aberrant immune responses and cause immunogenicity issues [96] . Similarly, the viral vector vaccines have proved to be excellent in preclinical and clinical phases for MERS and SARS-CoV; however, pre-existing vector immunity might reduce vaccine effectiveness [96] . Attenuated whole virus vaccines are a straightforward process, yet the relatively larger size of their genome can take a long time to create clones of the attenuated SARS-CoV-2 vaccine seeds [124] . Regardless of vaccine platforms, one key issue is the potential duration of immunity as the neutralizing antibody levels against SARS-CoV-2 seems to wear off relatively quickly, viz. within 2-3 months post-infection [125] . In contrast, recent work demonstrated that COVID-19 specific CD4+ and CD8+ T cell responses could be identified in 70% and 100% of convalescent patients, respectively, for months if not years [126] . Collectively these studies indicate that the frequency of vaccine doses needed to confer immunity may need to be closely monitored and/or adjusted accordingly.

J o u r n a l P r e -p r o o f

The social effects created by the global spread and pandemic of SARS-CoV-2 is showing beyond imaginable consequences that the world never faced in recent past decades. The total social impact is beyond comprehendible. After the health emergency declared by WHO, the world responded quickly to "flatten the curve" or limiting the spread of the virus by banning travels, closing non-essential businesses, closing educational institutions as well stopping all kind of large gatherings. Around half of the world's population are under full or partial lockdown currently to limit the spread of the deadly virus even after more than a year since the first case was reported in Wuhan, China [127] . Since people are staying at home due to COVID-19, the first impact arises inside the home in the form of exacerbating or sparking domestic violence, including physical, phycological, and sexual violence, or some form of child abuse [128] [129] [130] . The longer time staying at home due to the lockdown means more prolonged exposure of abuser to the victim. A recent study summarizes the increment of domestic violence in different developed countries around the world, counting France by 32% -36%, USA by 21%-35%, 5% increase in domestic abuse calls to police in Australia, and 25% increase calls to the helpline to report abuses in UK [131] .

On the other hand, more than 900 million learners are directly or indirectly affected by the closures of educational institutions from preschool to universities all over the world [132] . But, most of the developed countries avoided physical classroom activities and adopted online teaching with a campaign "School's Out, But Class's On" [133] . As a consequence of staying home for a more extended period, students are becoming more and more addicted to video games and pose the risk of setting unhealthy routine patterns [134] . Experts are concerned that this could increase childhood obesity as well as disparities in obesity risk [135] . The pandemic impacted religious activities in many ways, with canceling religious gatherings, worshiping of various faiths, religious festivities, and pilgrimages to religious sites [136, 137] . The kingdom of Saudi Arabia has provisionally cancelled the pilgrimage (Umrah as well as the yearly hajj) out of precaution to limit the spreading of the virus for the first time after the Kingdom of Saudi Arabia was formed [138] . Apart from all this, the social impacts of the pandemic have an advert effect on the mental health of individuals staying under lockdown for more extended periods, which intensified by anxiety, self-isolation, depression, and physical distancing [139] . Experts suggested that these factors could create perpetual fear and anxiety and also lead to suicidal tendencies [140] .

The extraordinary restrictions prompted by the raging SARS CoV-2 pandemic has halted the wide variety of economic events throughout the world. Gradually, the need for essential healthcare equipment demand is increasing parallelly with the raise of infected patients as well as death tolls. More than 100 countries have shut their borders [141] , and worldwide air travel demand plummeted just after the "Pandemic" announcement by WHO. This severely impacted the world's supply chain, as well as international trade [141] . The economists agreed that there would be an enormous negative impact on global economic development due to COVID-19, and this will possibly plunge the world economy into a deep recession [142] . The Organization for Economic Cooperation and Development (OECD) has predicted that the global GDP could decrease by 2% each month, potentially leading us to an economic shrinkage similar to the great depression in the 1930s [141] .

Millions of workers have lost/will lose their job, especially lower-income individuals or individuals working with daily wages [143] . Most of the workers related to retails and supply chain are exceptionally susceptible to COVID-19 in both health and monetarily as they are less likely to receive healthcare insurance provided by the employer [143] . In just five weeks after the pandemic, a record-breaking number of about 26 million Americans has filed for unemployment benefits, which clearly shows the impact of COVID-19 on US economy [144] .

Fears of exponential widespread of the virus severely impacted the US financial market. Dow Jones, stock market measuring index for the most significant 30 companies' stock performance listed in the stock market, has started losing points just after the USA outbreak and became lowest in the recent history on March 23, 2020 [145] . Due to the lockdown and other travel restriction measures caused by the pandemic, the oil consumption demand has evaporated severely. For the first time from the US oil market's record-keeping history, the crude oil price became negative, which means the producers are paying the buyers to purchase the oil. The price of crude oil in the USA has experienced a record drop of around 300% on April 20, 2020, and oil was traded as low as -$40.32 a barrel [146] .

The world tourism sector is experiencing an unexpected fall of between 20-30%, which is equivalent to $300-450 billion [124] , and this could lead many airline companies to go bankrupt [147] . Many European countries like Portugal, Spain, and Greece, whose GDP vastly depends on tourism, will get the worst hit by COVID-19 [142] . Hotels and restaurants are mostly closed all around the world, where lockdown measures are imposed. As a result, the price for agricultural products used in restaurants dropped by almost 20% [132] . The housing and real estate sector is another sector that is walloped by the pandemic. An online real estate database company Zillow has conducted a survey regarding housing prices during past pandemics and concluded that housing prices didn't drop or decrease much in most cases. Still, there was a drop in home/real estate property sales [148] . Moreover, there are many other sectors directly linked with the economy that are severely impacted by COVID-19 lockdown and social distancing measures. Of note, the impact of the COVID-19 pandemic will create a financial collapse, and it can potentially create a recession. Although different countries have started immediate relief packages to save the economy, it is still very soon to judge what would be the total economic impact of COVID-19 to the entire world.

We have seen a worldwide effort for effective administration of fighting against COVID-19 pandemic. In addition to current approaches, more potential drugs will be investigated for their performance and effectiveness towards COVID-19 in coming years. However, current mitigating measures especially social distancing and wearing masks are proven measures for limiting viral spread and can be adopted widely in regulation. On the other hand, more than two hundred candidates vaccines are pacing the R&D to expedite the development and clinical trial process to fight against the pandemic. We also foresee availability of effective vaccines for all within the next few years as already some vaccine candidates are approved, and few are in the final stage of the trials and should be available commercially soon. Although it is very early to say as a conventional method of vaccine development to a human application takes years to decades with investigating long term effects, but this pandemic showed the progression of half a decade's work within just five months. The development of vaccines for a novel disease like this will always be a challenge as it has to gain the trust of the scientific community first. There are challenges needs to overcome after the vaccine development in the stages like delivery, distribution, and administration. For an idyllic vaccine the production cost and storage cost should be minimum. So, it is also important that after the successful and innocuous development of the vaccines, the mass level of production, as well as the distribution of vaccines globally, needs to coordinate effectively to save human life.

Moreover, one major concern for developing a vaccine is to produce effective and preventive immune response against mutated and genetically drifted variants of SARS-CoV-2 strains. Cases of reinfection of COVID-19 for some patients suggests that immune response due to previous infection may not be effective or the immune response is not sustained for longer period [149] . Considerations should be given in innovative vaccine developments and also potentiality od application of combinational vaccines (two different type vaccines) can also be explored.

The recent pandemic will create a multidimensional adverse effect on the world. Although some regions or countries could mitigate the spread of the virus, there is always a fear of the resurge. Every day new results are coming out on different aspects of the virus as well as disease. Changing the mitigating strategy with the evolved results or findings are the keys to fight against this deadly virus. Global leadership, collaboration, accurate surveillance, tracking, and sharing information with the scientific committee require more coordination to overcome the global health emergency.

U. Demirci is a founder of and has an equity interest in: (i) DxNow Inc., a company that is developing microfluidic IVF tools and imaging technologies for point-of-care diagnostic solutions, (ii) Koek Biotech, a company that is developing microfluidic technologies for clinical solutions, (iii) Levitas Inc., a company focusing on developing microfluidic products for sorting rare cells from liquid biopsy in cancer and other diseases, and (iv) Hillel Inc., a company bringing microfluidic cell phone tools to home settings. UD's interests were viewed and managed in accordance with the conflict of interest policies. All other authors declare no financial conflict of interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. 

A simplified SARS-CoV-2 detection protocol for research laboratories

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement

The Presence of SARS-CoV-2 RNA in Feces of COVID-19 Patients

Coronavirus disease (COVID-2019) situation reports

China coronavirus: Six questions scientists are asking

NIH clinical trial of investigational vaccine for COVID-19 begins

The SARS-CoV-2 Vaccine Pipeline: an Overview

Timely development of vaccines against SARS-CoV-2

How will country-based mitigation measures influence the course of the COVID-19 epidemic?

Control Measures for SARS-CoV-2: A Review on Light-Based Inactivation of Single-Stranded RNA Viruses

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

The proximal origin of SARS-CoV-2

Science Forum: SARS-CoV-2 (COVID-19) by the numbers

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

An evidence review of face masks against COVID-19

Applying principles of behaviour change to reduce SARS-CoV-2 transmission

Point-of-care colorimetric analysis through smartphone video

Advances in Diagnostic methods for Zika Virus infection

Advances in HIV diagnosis and monitoring

An antibody panel for highly specific detection and differentiation of Zika virus

Diagnosis for COVID-19: current status and future prospects

Development of a flow-free magnetic actuation platform for an automated microfluidic ELISA

Development of a flow-free automated colorimetric detection assay integrated with smartphone for Zika NS1

Lab-on-a-Chip Zika Detection With Reverse Transcription Loop-Mediated Isothermal Amplification-Based Assay for Point-of-Care Settings

Development of a Point-of-Care Assay for HIV-1 Viral Load Using Higher Refractive Index Antibody-Coated Microbeads

Combination prevention for COVID-19

Face masks considerably reduce Covid-19 cases in Germany-A synthetic control method approach

Face masks: what the data say

Low-cost measurement of face mask efficacy for filtering expelled droplets during speech

Efficacy of face shields against cough aerosol droplets from a cough simulator

Principles of disinfectant use and safety operation in medical facilities during coronavirus disease 2019 (COVID-19) outbreak. SN Comprehensive

Estimating COVID-19 outbreak risk through air travel

Epidemiological investigation of the first 135 COVID-19 cases in Brunei: implications for surveillance, control, and travel restrictions

The trinity of COVID-19: immunity, inflammation and intervention

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug Repurposing

Candidate drugs against SARS-CoV-2 and COVID-19

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Treatments for COVID-19: Drugs being tested against the coronavirus

Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2

Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19

PFIZER INITIATES PHASE 1 STUDY OF NOVEL ORAL ANTIVIRAL THERAPEUTIC AGENT AGAINST SARS-COV-2

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

Remdesivir for the treatment of Covid-19-preliminary report

Hopes rise for coronavirus drug remdesivir

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Favipiravir versus arbidol for COVID-19: a randomized clinical trial

A review on favipiravir: the properties, function, and usefulness to treat COVID-19

COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs

Receptor Antagonists in Critically Ill Patients with Covid-19-Preliminary report

Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Artificial Intelligence (AI) applications for COVID-19 pandemic

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

Passive immunization. Plotkin's Vaccines

Convalescent plasma as a potential therapy for COVID-19

Active and passive immunity, vaccine types, excipients and licensing

7 -Passive immunization

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical microbiology and infection : the official publication of the

Treatment with convalescent plasma for COVID-19 patients in Wuhan

Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

29-year-old COVID-19 patient treated with Israel's new 'passive vaccine

Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

Convalescent Plasma and COVID-19

Supply and demand for plasma-derived medicinal products-A critical reassessment amid the COVID-19 pandemic

Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic

Lilly begins first clinical trial of antibody that targets SARS-CoV-2

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Neutralizing Antibodies against SARS-CoV-2: Current Understanding, Challenge and Perspective

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

COVID-19 Treatment: COVI-SHIELD (Neutralizing Antibody Cocktail)

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Monoclonal Antibodies for Prevention and Treatment of COVID-19

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infection

Janeway's immunobiology. Garland science

The race for coronavirus vaccines: a graphical guide

DRAFT landscape of COVID-19 candidate vaccines

The COVID-19 vaccine development landscape

SARS-CoV-2 Vaccine Development: An Overview and Perspectives

SARS-CoV-2 vaccines: status report

Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer

Vaccine-United States

Mandating COVID-19 Vaccines

COVID-19 vaccines poised for launch, but impact on pandemic unclear

CureVac Begins Phase IIb/III Trial of Its mRNA COVID-19 Vaccine

COVID-19 vaccines: where we stand and challenges ahead

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine-United States

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19

Russia's fast-track coronavirus vaccine draws outrage over safety

Russia announces positive COVID-vaccine results from controversial trial

COVID-19 vaccine frontrunners. The Scientist

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind

Covid-19: UK approves Oxford vaccine as cases of new variant surge

Latest results put Oxford-AstraZeneca COVID vaccine back on track

Covid-19: Doctors must be vaccinated without delay, says BMA

What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine

Development of an inactivated vaccine candidate for SARS-CoV-2

SARS vaccines speed towards clinic

HOW VACCINES WORK

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Immunogenicity of a DNA vaccine candidate for COVID-19

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

COVID-19 vaccine development and a potential nanomaterial path forward

The Battle Against COVID-19: Where Do We Stand Now?

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

Tourism and the Sustainable Development Agenda: Seizing opportunity in crisis. International Trade Forum, International Trade Centre

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

A third of the global population is on coronavirus lockdown

COVID-19: Reducing the risk of infection might increase the risk of intimate partner violence

Pandemics and violence against women and children

The psychological and social impact of Covid-19: new perspectives of well-being

Family violence and COVID-19: Increased vulnerability and reduced options for support

The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: A Review

School's Out, But Class' On', The Largest Online Education in the World Today: Taking China's Practical Exploration During The COVID-19 Epidemic Prevention and Control As an Example. But Class' On', The Largest Online Education in the World Today: Taking China's Practical Exploration During The COVID-19 Epidemic Prevention and Control As an Example

Problematic online gaming and the COVID-19 pandemic

COVID-19 Related School Closings and Risk of Weight Gain Among Children

The cancellation of mass gatherings (MGs)? Decision making in the time of COVID-19

Should the Holy Week 2020 be cancelled in Latin America due to the COVID-19 pandemic? Travel Medicine and Infectious Disease

COVID-19: Disease, management, treatment, and social impact

Patients with mental health disorders in the COVID-19 epidemic

Suicide risk and prevention during the COVID-19 pandemic. The Lancet Psychiatry

The World after COVID-19 and its impact on Global Economy

Economic effects of coronavirus outbreak (COVID-19) on the world economy

COVID-19 puts America's low-wage workforce in an even worse position

Record 26 million Americans filed for jobless benefits over 5 weeks as layoffs wind on

US oil price below zero for first time

Many of the world's airlines could be bankrupt by May because of the COVID-19 crisis

Information From Past Pandemics, And What We Can Learn: A Literature Review

Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment

COVID-19 Vaccine & Therapeutics Tracker

NYTIMES 2021

This manuscript has been supported by research support from the National Science Foundation (NSF) Rapid (2027890), and NSF CAREER (1942487).

J o u r n a l P r e -p r o o f